Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
Market Analysis and Insights: Global Short Bowel Syndrome (SBS) Drugs Market
The global Short Bowel Syndrome (SBS) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Short Bowel Syndrome (SBS) Drugs Scope and Market Size
Short Bowel Syndrome (SBS) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Short Bowel Syndrome (SBS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Short Bowel Syndrome (SBS) Drugs market is segmented into
Glucagon-Like Peptide-2 (GLP-2)
Growth Hormone
Glutamine
Other
Segment by Application, the Short Bowel Syndrome (SBS) Drugs market is segmented into
Hospitals
Clinics
Retail Pharmacies
Regional and Country-level Analysis
The Short Bowel Syndrome (SBS) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Short Bowel Syndrome (SBS) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Short Bowel Syndrome (SBS) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Short Bowel Syndrome (SBS) Drugs business, the date to enter into the Short Bowel Syndrome (SBS) Drugs market, Short Bowel Syndrome (SBS) Drugs product introduction, recent developments, etc.
The major vendors covered:
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
Market Analysis and Insights: Global Short Bowel Syndrome (SBS) Drugs Market
The global Short Bowel Syndrome (SBS) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Short Bowel Syndrome (SBS) Drugs Scope and Market Size
Short Bowel Syndrome (SBS) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Short Bowel Syndrome (SBS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Short Bowel Syndrome (SBS) Drugs market is segmented into
Glucagon-Like Peptide-2 (GLP-2)
Growth Hormone
Glutamine
Other
Segment by Application, the Short Bowel Syndrome (SBS) Drugs market is segmented into
Hospitals
Clinics
Retail Pharmacies
Regional and Country-level Analysis
The Short Bowel Syndrome (SBS) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Short Bowel Syndrome (SBS) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Short Bowel Syndrome (SBS) Drugs Market Share AnalysisShort Bowel Syndrome (SBS) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Short Bowel Syndrome (SBS) Drugs business, the date to enter into the Short Bowel Syndrome (SBS) Drugs market, Short Bowel Syndrome (SBS) Drugs product introduction, recent developments, etc.
The major vendors covered:
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.